Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia

Summary Summary Glucagon-like peptide-1 is an incretin hormone proposed to have insulinomimetic effects on peripheral insulin-sensitive tissue. We examined these effects on the heart by using isolated, perfused rat hearts and adult ventricular myocytes. During normoxic perfusion, no effects of escalating concentrations of GLP-1 on either heart rate or left ventricular developed pressure were found. With functional performance as readout, we found that GLP-1 directly protected the heart against damage incurred by global low-flow ischaemia. This protection was sensitive to the presence of iodo-acetate, implicating activation of glycolysis, and was abolished by wortmannin, indicative of PI-3-kinase as mediator of protection. In addition, GLP-1 had an infarct-sparing effect when supported by the presence of the dipeptidyl peptidase-IV inhibitor valine pyrrolidide. GLP-1 could not directly activate protein kinase B (also called Akt) or the extracellular regulated kinases Erk1/2 in hearts or cardiocytes under normoxic conditions, but phosphorylation of the AMP-activated kinase (AMPK) on Thr172 was enhanced. In addition, the glycolytic enzyme phosphofructokinase-2 was activated dose dependently. During reperfusion after ischaemia, modulation of the phosphorylation of PKB/Akt as well as AMPK was evident. GLP-1 therefore directly protected the heart against low-flow ischaemia by enhancing glycolysis, probably via activation of AMP kinase and by modulating the profile of activation of the survival kinase PKB/Akt.

• Publication year

  2008

• Venue

  Cardiovascular Journal of Africa

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 18516352PMCID 3975219
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts

  2006cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005cited by this paper
• What do we know about the secretion and degradation of incretin hormones?

  2005cited by this paper
• Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

  2005cited by this paper
• Impact of low-flow ischemia on substrate oxidation and glycolysis in the isolated perfused rat heart.

  2004cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper
• The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning

  2004cited by this paper
• Ischemic preconditioning: Infarct size is a more reliable endpoint than functional recovery

  2003cited by this paper
• Akt Activity Negatively Regulates Phosphorylation of AMP-activated Protein Kinase in the Heart*

  2003cited by this paper
• Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons.

  2002cited by this paper
• Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.

  2002cited by this paper
• Effect of Vanadate and Insulin on Glucose Transport in Isolated Adult Rat Cardiomyocytes

  2000cited by this paper
• Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia.

  2000cited by this paper
• Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

  1998cited by this paper
• GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor.

  1998cited by this paper
• GLP-1 (7 - 36) Amide: Effects on Glucose Transport and Metabolism in Rat Adipose Tissue

  1997cited by this paper
• Distribution of GLP-1 and PACAP receptors in human tissues.

  1996cited by this paper
• Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

  1996cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• Enteral Enhancement of Glucose Disposition by Both Insulin-Dependent and Insulin-Independent Processes: A Physiological Role of Glucagon-Like Peptide I

  1995cited by this paper
• Glucagon-like peptide-1 binding to rat hepatic membranes.

  1995cited by this paper
• Glucagon‐like peptide 1: A potent glycogenic hormone

  1994cited by this paper
• Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats.

  1994cited by this paper
• Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.

  1994cited by this paper
• Potent glycogenic effect of GLP-1(7–36)amide in rat skeletal muscle

  1994cited by this paper
• Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.

  1994cited by this paper
• Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action.

  1994cited by this paper
• Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue.

  1993cited by this paper
• Solubilization of active receptors for glucagon-like peptide-1(7-36)amide from rat lung membranes.

  1993cited by this paper
• A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate.

  1982cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Pancreatic Glucagon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells*

  year unknowncited by this paper

• Enteral Lactoferrin Mitigates Myocardial ischemia-reperfusion Injury Via Enteral Lactoferrin-induced glucagon-like peptide-1 in Isolated Rat Heart Model

  2025cites this paper
• Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets

  2025cites this paper
• GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome/PFKFB3-driven glycolysis interaction and histone lactylation

  2024cites this paper
• Role of the protein kinase A signaling pathway and identification of mediators in the cardioprotective effects of enteral lactoferrin for ischemia-reperfusion injury in an isolated rat heart model.

  2023cites this paper
• Potential Role of GLP-1 Based Therapeutics in Coronary Artery Disease.

  2023cites this paper
• Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)

  2021cites this paper
• Rosuvastatin protects isolated hearts against ischemia-reperfusion injury: role of Akt-GSK-3β, metabolic environment, and mitochondrial permeability transition pore

  2020cites this paper
• Notch signaling is involved in the antiapoptotic effects of liraglutide on rat H9c2 cardiomyocytes exposed to hypoxia followed by reoxygenation

  2020cites this paper
• Pyrrolidine dithiocarbamate and saxagliptin ameliorate ulcerative colitis in rats

  2019cites this paper
• Melatonin has profound effects on mitochondrial dynamics in myocardial ischaemia/reperfusion

  2019cites this paper
• Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

  2018cites this paper
• Molecular and clinical roles of incretin-based drugs in patients with heart failure

  2018cites this paper
• Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury

  2018cites this paper
• An investigation into the importance of the ATM protein in the myocardial pathology associated with insulin resistance and type 2 diabetes

  2017cites this paper
• New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury.

  2017cites this paper
• Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes.

  2016cites this paper
• The role of Atm in the regulation of cardiomyocyte glucose utilization under normal and insulin resistant conditions

  2016cites this paper
• The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways

  2016cites this paper
• Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data?

  2016cites this paper
• Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists

  2016cites this paper
• Systemic effects Improved glucose metabolism Increased vasodilation Inflammatory cells Weight loss Blood pressure decrease Reduction of atherosclerotic lesions Liver and pancreas

  2015cites this paper
• Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs.

  2015cites this paper
• Effects of exendin-4, a glucagon like peptide-1 receptor agonist, on neutrophil count and inflammatory cytokines in a rat model of endotoxemia

  2015cites this paper
• Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart

  2015cites this paper
• Protective effects of extendin‑4 on hypoxia/reoxygenation‑induced injury in H9c2 cells.

  2015cites this paper
• Inhibition of DPP-4 reduces acute mortality after myocardial infarction with restoration of autophagic response in type 2 diabetic rats

  2015cites this paper
• Incretin therapy and heart failure.

  2014cites this paper
• Cardiovascular and hemodynamic effects of glucagon-like peptide-1

  2014cites this paper
• Effect of exenatide on the cardiac expression of adiponectin receptor 1 and NADPH oxidase subunits and heart function in streptozotocin-induced diabetic rats

  2014cites this paper
• Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus

  2013cites this paper
• Glucagon-like peptide-1 preserves coronary microvascular endothelial function after cardiac arrest and resuscitation: potential antioxidant effects.

  2013cites this paper
• Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.

  2013cites this paper
• AMPK activation—protean potential for boosting healthspan

  2013cites this paper
• DPP 4 (dipeptidylpeptidase-4) inhibitors: beyond glycemic control

  2013cites this paper
• Coronary Microvascular Dysfunction in CAD: Consequences and Potential Therapeutic Applications

  2012cites this paper
• Non-Insulin Injectable Treatments (Glucagon-Like Peptide-1 and Its Analogs) and Cardiovascular Disease

  2012cites this paper
• Cyclic AMP and PKA: How can a Lot of Good Come from the Potentially Bad?

  2012cites this paper
• Renal and Cardiac Effects of DPP4 Inhibitors – from Preclinical Development to Clinical Research

  2012cites this paper
• Glucagon-like peptide 1 and cardiac cell survival

  2012cites this paper
• Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury.

  2012cites this paper
• Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms

  2012cites this paper
• Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca

  2012cites this paper
• Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow

  2012cites this paper
• GLP-1 and cardioprotection: from bench to bedside.

  2012cites this paper
• Glucagon-like peptide 1 and cardiac cell survival.

  2012cites this paper
• Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes.

  2011cites this paper
• The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury

  2011cites this paper
• Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents

  2011cites this paper
• Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats

  2011cites this paper
• Cardiovascular effects of glucagon-like peptide 1.

  2011cites this paper
• Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction.

  2010cites this paper
• Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes.

  2010cites this paper
• Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances

  2010cites this paper
• Transitory Activation of AMPK at Reperfusion Protects the Ischaemic-Reperfused Rat Myocardium Against Infarction

  2010cites this paper
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

  2008cites this paper
• Antiapoptotic Effects of Glp-1 in Murine Hl-1 Cardiomyocytes Hl-1 Cell Culture Hl-1 Murine Cells Were a Gift From

  year unknowncites this paper